Mon Oct 06 09:10:58 UTC 2025: **Summary:**

Eli Lilly and Company will invest over $1 billion in India, including establishing a new manufacturing and quality facility in Hyderabad. This investment will expand the company’s manufacturing and supply capabilities to support its growing portfolio. The new facility in Hyderabad will be a hub for Lilly’s contract manufacturing network across India, creating numerous job opportunities. The expansion signifies Lilly’s confidence in India’s capabilities and its commitment to the “Make in India” agenda. The Telangana Chief Minister welcomes the investment, highlighting Hyderabad’s growing prominence in global healthcare innovation.

**News Article:**

**Eli Lilly to Invest Over $1 Billion in India, Establishing New Manufacturing Hub in Hyderabad**

**HYDERABAD, October 6, 2025** – Global pharmaceutical giant Eli Lilly and Company announced today that it will invest over $1 billion in India over the next several years, solidifying its presence in the country and boosting the “Make in India” initiative. The investment includes the establishment of a new state-of-the-art manufacturing and quality facility in Hyderabad, further cementing the city’s position as a rising hub for global healthcare innovation.

According to Patrik Jonsson, Executive Vice President and President of Lilly International, the investment will significantly strengthen the company’s manufacturing and supply capabilities to support its evolving portfolio. “We are making significant investments to increase manufacturing and medicine supply capacity around the world to help ensure patients have access to the medicines they need,” Jonsson stated.

The Hyderabad facility will serve as a central hub providing advanced technical expertise and oversight for Lilly’s contract manufacturing network across India. Recruitment for the new facility will begin immediately, with open positions for engineers, chemists, analytical scientists, quality control and assurance professionals, and management positions.

Telangana Chief Minister A. Revanth Reddy hailed the investment as a testament to Hyderabad’s growing prominence in the global healthcare sector. “Lilly’s continued expansion in Hyderabad highlights the city’s emergence as a powerhouse in global healthcare innovation,” he said. “The decision reinforcing the State’s position as a preferred destination for cutting-edge healthcare investments.”

Industries and IT Minister D. Sridhar Babu echoed the Chief Minister’s sentiments, emphasizing Telangana’s dynamic industrial landscape and its focus on technology-driven infrastructure and ease of doing business.

The investment follows Lilly’s global commitment of over $55 billion since 2020 to expand and acquire facilities in the U.S. and around the world. This reflects the company’s preparations for potential new medicines targeting diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune conditions. Eli Lilly currently has a commercial site in Gurugram and specialised sites in Bengaluru and Hyderabad that support global innovation.

This significant investment by Eli Lilly is expected to have a substantial impact on India’s pharmaceutical industry, creating numerous jobs and contributing to the country’s growing role in global healthcare manufacturing.

Read More